What Is Liver Cancer?
Liver cancer develops when abnormal cells grow uncontrollably within the liver. Primary liver cancer begins in the liver itself, while secondary or metastatic liver cancer occurs when cancer spreads to the liver from another part of the body. Important risk factors for primary liver cancer include chronic hepatitis B or C infection, cirrhosis, alcohol-associated liver disease, and metabolic dysfunction-associated steatotic liver disease (MASLD). At Saint John’s Cancer Institute, multidisciplinary evaluation helps determine the type of liver tumor and the most appropriate treatment options.

The liver performs essential functions, including processing nutrients, producing bile, regulating metabolism, and filtering substances from the bloodstream. Cancer affecting the liver can interfere with these functions, particularly when the liver is already damaged by chronic disease.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer in adults. It develops from hepatocytes, the principal cells of the liver. Intrahepatic cholangiocarcinoma, which arises from bile duct cells within the liver, is another important form of primary liver cancer. Longstanding liver inflammation and scarring can increase cancer risk. Hepatitis B and C infections are important causes worldwide, while cirrhosis can develop from viral hepatitis, excessive alcohol consumption, or metabolic liver disease. Hepatitis B can sometimes cause liver cancer even without cirrhosis.
Additional risk factors include certain inherited metabolic disorders and exposure to aflatoxins, toxins produced by particular molds that may contaminate food. Aflatoxins can contribute to DNA damage, including changes affecting the TP53 tumor suppressor gene. Some patients at increased risk of hepatocellular carcinoma benefit from regular liver surveillance, typically involving ultrasound and a blood test for alpha-fetoprotein (AFP) approximately every six months. Surveillance recommendations depend on the underlying liver condition and individual risk.
Types of Liver Cancer and Liver Tumors
Not every mass found in the liver is cancerous. Malignant tumors may originate within liver tissue or spread there from another organ, while benign liver lesions are often discovered during imaging performed for unrelated reasons.
Identifying the type of lesion is essential because different forms of liver cancer require different treatment approaches, while many benign tumors need no treatment.
Cancerous Liver Tumors
Malignant liver tumors either originate within liver tissue or represent metastatic disease from a cancer elsewhere in the body. The majority of malignant tumors found in the liver are metastatic rather than primary liver cancers.
Primary liver cancers differ substantially in their causes, biological behavior, and treatment. The most important types include hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma is the most common primary liver cancer in adults. It develops from hepatocytes and frequently occurs in patients with cirrhosis or chronic liver disease, although it can also develop in people without cirrhosis. HCC may appear as a single tumor, several separate tumors, or more extensive disease involving different areas of the liver. Both the number and size of tumors and the condition of the surrounding liver influence treatment recommendations. Risk factors include chronic hepatitis B or C infection, alcohol-associated cirrhosis, metabolic liver disease, hereditary hemochromatosis, and selected environmental exposures.
In patients with cirrhosis or other qualifying high-risk conditions, characteristic findings on multiphase CT or MRI can sometimes establish an HCC diagnosis without a biopsy. Other patients may require tissue sampling. One uncommon form of primary liver cancer is fibrolamellar carcinoma, which often develops in adolescents and younger adults without underlying cirrhosis. Its clinical behavior and treatment considerations differ from conventional HCC, making specialized evaluation important.
Intrahepatic Cholangiocarcinoma (Bile Duct Cancer)
Intrahepatic cholangiocarcinoma develops from cells lining the bile ducts within the liver. It is distinct from hepatocellular carcinoma and may require different surgical, medical, and molecularly targeted treatment approaches. Risk factors can include chronic inflammation of the bile ducts, primary sclerosing cholangitis, certain congenital bile duct abnormalities, and selected chronic liver infections. Surgical removal offers an opportunity for long-term disease control or cure in some patients with localized, resectable tumors. Patients with advanced disease may benefit from systemic therapy, molecular testing, and consideration of clinical trials.
Angiosarcoma and Other Rare Liver Cancers
Hepatic angiosarcoma is an extremely rare cancer arising from cells lining blood vessels in the liver. Historically recognized risk factors include certain occupational or environmental exposures, such as vinyl chloride and thorium dioxide. These tumors can behave aggressively and may be difficult to treat when diagnosed at an advanced stage. Treatment is individualized according to disease extent, the patient’s condition, and available specialist expertise.
Hepatoblastoma
Hepatoblastoma is a rare primary liver cancer that occurs predominantly in infants and young children. Diagnosis and treatment are generally managed by pediatric oncology specialists and may involve chemotherapy, surgery, and occasionally liver transplantation. Hepatoblastoma is biologically different from the primary liver cancers most commonly diagnosed in adults.
Secondary or Metastatic Liver Cancer
Metastatic liver cancer occurs when cancer cells spread to the liver from another organ, such as the colon, pancreas, stomach, breast, or lung. These tumors retain the characteristics of the cancer from which they originated. For example, colorectal cancer that spreads to the liver is still classified and treated as metastatic colorectal cancer, not primary liver cancer. Treatment depends on the original tumor type, the extent of spread, molecular characteristics, and whether surgery or other localized treatments may be appropriate. Selected patients with limited liver metastases may benefit from resection, ablation, histotripsy, radiation, or other therapies as part of an individualized multidisciplinary treatment plan.
Noncancerous Liver Tumors
Benign liver lesions generally do not invade nearby tissues or spread to distant organs. Many are asymptomatic and require only observation or no further follow-up once a confident diagnosis has been established. Others may need surveillance or treatment because of their size, symptoms, or potential complications.
Hemangioma
Hepatic hemangiomas are common benign growths composed of blood vessels. Most cause no symptoms and require no treatment when their diagnosis is confirmed through appropriate imaging.Large or symptomatic hemangiomas may occasionally require additional evaluation, particularly when they cause persistent discomfort or compress nearby structures. Surgery is uncommon and generally reserved for selected complications or significant symptoms.
Hepatic Adenoma
Hepatic adenomas are uncommon benign tumors that develop from hepatocytes. Some are associated with hormone exposure, including certain hormonal contraceptives or anabolic steroids, while others occur in association with obesity or metabolic conditions. Most do not cause symptoms, but some adenomas can bleed or undergo malignant transformation. Management depends on tumor size, growth, subtype, patient sex, and other risk factors. Treatment may involve medication or hormone adjustments, weight management, imaging surveillance, embolization, or surgery when indicated.
Focal Nodular Hyperplasia (FNH)
Focal nodular hyperplasia is a benign, tumor-like liver lesion associated with changes in local blood flow. It is commonly discovered incidentally during abdominal imaging. When FNH is confidently identified through appropriate imaging, treatment or continued surveillance is generally unnecessary. MRI with liver-specific contrast may help distinguish FNH from hepatic adenomas or other lesions when the diagnosis is uncertain.
Liver Cysts

Simple liver cysts are fluid-filled structures that are commonly benign and frequently discovered during ultrasound, CT, or MRI examinations. Most cause no symptoms and do not require treatment.
Larger cysts may occasionally produce abdominal discomfort or pressure on nearby organs. Symptomatic cysts can sometimes be treated with minimally invasive procedures, including laparoscopic fenestration, which opens part of the cyst wall. Complex cysts or cysts with unusual imaging features may require additional evaluation.
Symptoms of Liver Cancer
Liver cancer may cause few or no noticeable symptoms during its early stages. This is one reason surveillance is important for selected patients with cirrhosis, chronic hepatitis B, or other conditions associated with increased hepatocellular carcinoma risk.
When symptoms develop, they may result from the tumor itself, impaired liver function, or an underlying liver condition. Symptoms vary widely and do not necessarily indicate the presence of cancer.

Possible symptoms of primary liver cancer include:
- Pain or discomfort in the upper-right abdomen
- Unexplained weight loss
- Loss of appetite or feeling full after eating small amounts
- Persistent fatigue or weakness
- Nausea or vomiting
- Abdominal swelling or fluid accumulation (ascites)
- A noticeable fullness or mass in the upper abdomen
- Jaundice, including yellowing of the skin or eyes
- Dark urine or pale-colored stools
- Persistent itching
- Swelling of the legs or ankles
These symptoms can also occur with hepatitis, cirrhosis, gallbladder disease, and other noncancerous conditions. Persistent or unexplained symptoms should be discussed with a healthcare professional.
Symptoms of Metastatic Liver Cancer
Cancer that spreads to the liver from another organ may produce symptoms similar to those of primary liver cancer. Some patients have no liver-related symptoms and are diagnosed when imaging is performed to evaluate or monitor their original cancer.
Possible Symptoms
- Unexplained weight loss or decreased appetite
- Fatigue or generalized weakness
- Upper abdominal discomfort or fullness
- Enlargement of the liver
- Nausea or digestive discomfort
- Abdominal fluid accumulation (ascites)
- Jaundice or itching when bile flow or liver function is affected
Symptoms depend on the type of primary cancer, the extent of liver involvement, and the function of the remaining healthy liver tissue.
New jaundice, rapidly worsening abdominal swelling, or significant unexplained weight loss warrants prompt medical evaluation. Confusion, marked drowsiness, or signs of severe liver dysfunction require urgent medical attention.
Diagnosing Liver Cancer
Diagnosing liver cancer involves determining whether a liver lesion is benign or malignant, identifying the type of cancer, and evaluating how extensively the disease affects the liver and other organs.
The diagnostic process may involve blood tests, ultrasound, contrast-enhanced CT or MRI, and, in selected circumstances, a liver biopsy. Patients with chronic liver disease may also undergo assessment of underlying cirrhosis and liver function because these findings can influence treatment.
Diagnostic Tests and Imaging

Diagnostic testing is selected according to the patient’s history, liver disease risk factors, and initial imaging findings. Common methods include:
- Abdominal Ultrasound: Uses sound waves to examine the liver and identify suspicious masses. It is also commonly used for surveillance in patients at increased risk of HCC.
- Multiphase CT: Provides detailed images after intravenous contrast administration and helps characterize liver tumors, blood vessels, and possible spread.
- Contrast-Enhanced MRI: Provides detailed information about liver lesions and can help distinguish certain benign and malignant abnormalities.
- Blood Tests: Liver function tests, blood counts, clotting studies, and tumor markers such as alpha-fetoprotein (AFP) may contribute to evaluation. AFP alone cannot reliably confirm or exclude liver cancer.
- Liver Biopsy: Tissue sampling may be recommended when imaging is inconclusive or the diagnosis will affect treatment. In selected high-risk patients, HCC can be diagnosed through characteristic imaging findings without biopsy.
- MRCP or ERCP: Specialized imaging or endoscopic procedures may help evaluate bile ducts when cholangiocarcinoma or a biliary obstruction is suspected.
- Additional Imaging: Chest imaging or other studies may be recommended to determine whether cancer has spread beyond the liver.
Evaluating Liver Function
Unlike many other cancers, hepatocellular carcinoma frequently occurs in patients with preexisting liver disease. Assessment may include bilirubin, albumin, clotting function, fluid accumulation, and other signs of cirrhosis or portal hypertension.
These findings help determine whether the liver can tolerate surgery, localized treatment, or systemic therapy. In some patients, the condition of the remaining liver is as important as the size or number of tumors.
Liver Cancer Stages
Staging helps determine how extensively cancer involves the liver, whether blood vessels or nearby structures are affected, and whether it has spread to other parts of the body.
For hepatocellular carcinoma, treatment planning often uses the Barcelona Clinic Liver Cancer (BCLC) system, which considers tumor characteristics, liver function, and the patient’s general physical condition. Other staging systems, including TNM, may also be used for particular clinical purposes.
Very Early or Early Stage (BCLC 0–A)
Cancer is generally limited to the liver, with a small or limited number of tumors and sufficient liver function for consideration of potentially curative treatment. Depending on the patient’s condition, options may include surgical removal, liver transplantation, or tumor ablation.
Intermediate Stage (BCLC B)
Cancer involves multiple areas of the liver but has not necessarily spread beyond it. Liver function and overall health remain important in determining treatment. Options may include transarterial therapies, selected systemic treatments, or other individualized approaches.
Advanced Stage (BCLC C)
Cancer may involve major blood vessels, spread to lymph nodes or distant organs, or meet other criteria for advanced disease. Systemic treatments, including immunotherapy and targeted medications, are often considered for eligible patients. Radiation and other localized treatments may also be appropriate in selected circumstances.
End-Stage Disease (BCLC D)
Severely impaired liver function or poor overall physical condition may limit the safety and benefit of cancer-directed treatment. Care emphasizes symptom relief, quality of life, and support for patients and families. Selected patients may still be evaluated for liver transplantation when clinically appropriate.
These categories primarily describe hepatocellular carcinoma. Intrahepatic cholangiocarcinoma and metastatic liver tumors use different staging and treatment frameworks based on their specific cancer type.

Liver Cancer Treatment Summary
Treatment for liver cancer depends on whether the cancer originated in the liver or spread from another organ, the tumor’s size and location, the extent of disease, and the patient’s overall health. For hepatocellular carcinoma, the condition of the remaining liver is especially important.
Multidisciplinary planning may involve surgical oncologists, hepatologists, medical oncologists, interventional radiologists, radiation oncologists, and other specialists. Depending on the diagnosis, treatment options may include surgery, transplantation, localized tumor destruction, embolization, radiation, immunotherapy, or targeted medications.
Surgery and Liver Resection
Surgery may offer an opportunity for cure in selected patients with localized primary liver cancer or certain liver metastases. A liver resection removes the affected portion of the liver while preserving enough healthy tissue to maintain essential liver function.
Eligibility depends on the tumor’s location and extent, vascular involvement, underlying liver disease, and the amount of functioning liver that would remain after surgery. Minimally invasive or robotic-assisted procedures may be appropriate for selected patients.
Liver Transplantation
For certain patients with hepatocellular carcinoma and significant underlying liver disease, liver transplantation may provide an opportunity to treat both the cancer and the damaged liver. Eligibility depends on tumor burden, liver function, overall health, transplant criteria, and donor availability.
Patients who may benefit from transplantation require specialized evaluation. Treatment intended to control the tumor may sometimes be used while awaiting transplantation or to help meet transplant eligibility criteria.
Histotripsy (Focused Ultrasound)

Histotripsy is a noninvasive treatment technique that uses precisely focused ultrasound pulses to mechanically break down targeted liver tissue. Unlike thermal ablation, histotripsy does not rely primarily on heating or freezing the tumor.
The technology offers an additional localized treatment option for selected patients with liver tumors. Its suitability depends on tumor size, number, position, visibility during treatment, and proximity to critical structures.
Histotripsy can achieve destruction of targeted tumor tissue in appropriately selected cases, but it does not guarantee that all cancer has been eliminated or that recurrence will be prevented. Clinical evaluation, follow-up imaging, and sometimes additional treatment remain important.
Learn more about Histotripsy for Liver Tumors at Saint John’s Health Center.
Thermal Ablation and Other Localized Treatments
Ablation destroys targeted tumor tissue using techniques such as radiofrequency or microwave energy. Certain small liver tumors can be treated without removing a portion of the liver, particularly when surgery is unsuitable.
Other techniques, including cryoablation or selected nonthermal treatments, may be considered depending on tumor characteristics and available expertise. Some patients require more than one session or continued surveillance after treatment.
Radiation Therapy
Radiation therapy uses focused high-energy radiation to damage cancer cells. Techniques such as stereotactic body radiation therapy (SBRT) may be considered for selected liver tumors when surgery or other localized procedures are unsuitable.
Radiation may also help control specific areas of cancer or relieve symptoms. Treatment planning considers the location of the tumor and the amount of radiation that healthy liver tissue and nearby organs can safely tolerate.
Embolization and Liver-Directed Therapy
Embolization treatments target the blood vessels supplying liver tumors. Transarterial chemoembolization (TACE) delivers chemotherapy directly into selected tumor-feeding arteries while reducing their blood supply. Other approaches may use embolization without chemotherapy or deliver radioactive particles through the hepatic arteries.
These procedures can be useful for selected patients with liver-confined cancer who are not candidates for surgery or other curative treatment. Suitability depends on liver function, the pattern of tumor involvement, and other medical considerations.
Immunotherapy
Immunotherapy helps the immune system recognize and attack cancer cells. Immune checkpoint inhibitors have become important systemic treatment options for selected patients with advanced or unresectable hepatocellular carcinoma.
Depending on the clinical circumstances, treatment may involve combinations such as atezolizumab with bevacizumab, durvalumab with tremelimumab, or other approved immunotherapy regimens. Treatment selection considers liver function, bleeding risk, autoimmune conditions, previous therapies, and potential side effects.
Targeted Drug Therapy
Targeted medications interfere with specific biological pathways involved in tumor growth or blood vessel development. Treatments used for selected patients with advanced hepatocellular carcinoma include agents such as lenvatinib, sorafenib, cabozantinib, and other drugs chosen according to the treatment setting.
For intrahepatic cholangiocarcinoma, molecular testing may identify genetic alterations that make certain targeted therapies appropriate. These treatment options differ from those used for hepatocellular carcinoma.
Chemotherapy
Conventional systemic chemotherapy has a more limited role in hepatocellular carcinoma than immunotherapy and targeted medications. However, chemotherapy remains important for other cancers involving the liver, including many cases of cholangiocarcinoma and metastatic disease originating from the gastrointestinal tract or other organs.
The appropriate treatment regimen depends on the original cancer type, disease stage, molecular findings, and previous treatment.
Supportive Care and Liver Health
Managing underlying liver disease is an essential part of care for many patients with liver cancer. Treatment may include addressing viral hepatitis, controlling complications of cirrhosis, optimizing nutrition, and managing symptoms such as pain, fatigue, or abdominal fluid accumulation.
Supportive care can be provided alongside cancer treatment to improve comfort, preserve function, and help patients maintain the best possible quality of life.
Learn More About Liver Cancer Treatment
Explore our Liver Cancer Treatment page to learn more about surgical, minimally invasive, liver-directed, and systemic treatment options.

At Saint John’s Cancer Institute, our multidisciplinary approach brings together specialists in surgical oncology, medical oncology, hepatology, interventional radiology, and radiation oncology to evaluate complex liver tumors and develop individualized treatment plans.
Through coordinated clinical expertise, minimally invasive treatment options, and supportive care, we help patients and families understand their diagnosis, consider available therapies, and make informed decisions about the next steps in their care.
If you have questions regarding Liver Cancer and symptoms, please call today. Click here to request an appointment.
